Product Description
The global peripheral intravascular lithotripsy (IVL) market was valued at $335 million in 2025. This is expected to increase over the forecast period at a CAGR of 23.3% to reach $1.4 billion by 2032.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Peripheral Intravascular Lithotripsy (IVL) Market Trends
An ongoing trend in the global IVL market is the increasing adoption of this innovative technology for treating complex calcified coronary artery lesions. IVL offers a safe and effective approach to address challenging calcifications, allowing for optimal stent deployment and expansion. The technique’s ability to modify calcified lesions while minimizing vessel trauma has gained traction among interventional cardiologists, leading to its integration as a valuable tool in percutaneous coronary interventions. This trend is driven by the growing recognition of IVL’s potential to improve procedural outcomes and enhance patient care in cases involving severely calcified arteries.
Peripheral Intravascular Lithotripsy (IVL) Market Share Insights
- Johnson & Johnson completed its acquisition of Shockwave Medical in 2024, the sole competitor in the IVL market, further strengthening Johnson & Johnson MedTech’s leadership in cardiovascular intervention. The company’s flagship product, the Peripheral Lithoplasty® Balloon Dilation Catheter, first received Food and Drug Administration (FDA) approval for peripheral use in September 2016. Since then, Shockwave has advanced multiple clinical programs, including the DISRUPT II and III trials in the fem-pop artery and the DISRUPT BTK and BTK II trials evaluating IVL below the knee. In September 2019, Shockwave’s Lithoplasty® balloon also gained FDA approval for coronary use, further expanding its clinical and commercial reach.
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
